当前位置：药药网 / 数据中心 /奥大利亚药品评审报告(本栏目收费,不能显示细节,电话15274084725)
药品名称：
活性成份：
发布日期：-
奥大利亚药品评审报告745个记录(本栏目收费,不能显示细节,电话15274084725)
奥大利亚药品评审报告
1
Qarziba
Dinutuximab beta
2020/6/30
2
Remsima, Emisima, Flixceli, Inflectra
Infliximab (rmc)
2020/6/3
3
Taltz
Ixekizumab
2020/6/22
4
Idhifa
Enasidenib
2020/4/24
5
Lenvima
Lenvatinib (as mesilate)
2020/5/5
6
Rinvoq
Upadacitinib
2020/4/24
7
Cequa
Ciclosporin
2020/4/24
8
Cablivi
Caplacizumab
2020/5/5
9
Keytruda
Pembrolizumab (rch)
2020/5/5
10
Nerlynx
Neratinib (as maleate)
2020/5/12
11
Arixtra
Fondaparinux
2020/5/11
12
Xofluza
Baloxavir marboxil
2020/6/4
13
Tecentriq
Atezolizumab
2020/6/4
14
Beovu
Brolucizumab (rbe)
2020/4/14
15
Vimpat
Lacosamide
2020/1/30
16
Opdivo
Nivolumab
2020/1/24
17
Skyrizi
Risankizumab
2020/1/22
18
Evenity
Romosozumab
2020/1/20
19
Oripro
Progesterone
2020/2/7
20
Raxone
Idebenone
2020/2/6